Shares of Hemostemix Inc. (CVE:HEM – Get Free Report) traded up 46.7% during trading on Saturday . The stock traded as high as C$0.11 and last traded at C$0.11. 1,473,342 shares were traded during trading, an increase of 283% from the average session volume of 384,669 shares. The stock had previously closed at C$0.08.
Hemostemix Stock Performance
The company has a debt-to-equity ratio of -55.07, a current ratio of 0.04 and a quick ratio of 0.48. The firm has a market capitalization of C$19.58 million, a price-to-earnings ratio of -2.97 and a beta of 1.39. The firm’s fifty day moving average is C$0.11 and its 200 day moving average is C$0.12.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Read More
- Five stocks we like better than Hemostemix
- Where to Find Earnings Call Transcripts
- Engines to AI: Cummins’ Surprising Growth Driver
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Smaller Industrials Names Seeing Surging Growth: Here’s Why
- Profitably Trade Stocks at 52-Week Highs
- MarketBeat Week in Review – 08/25 – 08/29
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
